Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market

HUDDINGE, Sweden, March 23, 2022 /PRNewswire/ -- The prospectus relating to the rights issue in Karo Pharma Aktiebolag ("Karo Pharma") of approximately SEK 2.5 billion (the "Rights Issue") has

Related Keywords

Australia ,Japan ,United States ,New Zealand ,Hong Kong ,Stockholm ,Sweden ,United Kingdom ,Singapore ,South Africa ,Canada ,Switzerland ,Huddinge ,Swedish ,Karo Pharma ,Christoffer Lorenzen ,Skandinaviska Enskilda Banken ,Karo Pharma Aktiebolag ,Jon Johnsson ,Swedish Financial Supervisory Authority ,Erik Penser Bank ,European Parliament ,European Union Withdrawal ,Financial Services ,Swedbank ,Swedish Financial Supervisory ,Nasdaq Stockholm ,Nasdaq First North Growth ,Nasdaq First North Growth Market ,Rights Issue ,Joint Global Coordinators ,Case Advokataktiebolag ,Certified Advisor ,Nasdaq Stockholm Large ,United States Securities Act ,Relevant State ,European Union ,Markets Act ,Financial Promotion ,Bokaro ,Dharma ,Ublishes ,Prospectus ,Elating ,Tights ,Issue ,Eceives ,Approval ,Change ,Listing ,Revenue ,Nasdaq ,First ,North ,Growth ,Market ,